In This Section

Sarah K. Tasian, MD
Sarah K. Tasian
Attending Physician

Dr. Tasian's research centers on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.



Subscribe to be notified of changes or updates to this page.


Dr. Tasian's translational research program aims to develop targeted therapeutic strategies for high-risk childhood leukemias. To accomplish this, her research program focuses on the characterization of intracellular signal transduction networks and preclinical testing of kinase inhibitors in genetic subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). She conducts preclinical testing of chimeric antigen receptor (CAR) T-cell immunotherapies for AML and ALL, as well as early-phase clinical testing of molecularly-targeted therapies for children with leukemia through the Children’s Oncology Group and other consortia.

Dr. Tasian has substantial expertise in investigation of kinase inhibitors and CAR T-cell immunotherapies in specialized patient-derived xenograft models of childhood and adult ALL and AML, as well as in phosphosignaling analyses and measurement of patients' molecular responses to kinase inhibitors. Successful integration of her bench-based and clinical studies has led to several early-phase clinical trials testing new therapies in children with high-risk leukemias.

Education and Training

BS and BA, University of Notre Dame (Biological Sciences and Psychology), 1999

MD, Baylor College of Medicine, 2004

Fellowship, University of California, San Francisco (Pediatric Hematology-Oncology), 2010

Titles and Academic Titles

Attending Physician

Associate Professor of Pediatrics

Professional Memberships

American Society of Hematology, 2007-

Children's Oncology Group, 2008-

American Association for Cancer Research, 2008-

American Society of Pediatric Hematology-Oncology, 2009-

American Society of Clinical Oncology, 2010-

International Society of Paediatric Oncology, 2014-

European Hematology Association, 2016-

Professional Awards

ASCO Trainee Travel Award, 2010

ASH Travel Award, 2010

Alex's Lemonade Stand Foundation Young Investigator Award, 2012

CCCR Canuso Foundation Innovation Award, 2013

ALSF Scholar in Developmental Therapeutics, 2013

Publication Highlights

Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia. 2019 Jan; 33(1):181-190. PMID: 29884903
Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Li F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen I-M, Willman CL, Hunger SP, Li MM, Tasian SK. Clinical Efficacy of Ruxolitinib and Chemotherapy in a Child with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia with GOLGA5-JAK2 Fusion and Induction Failure. Haematologica. 2018 Sep; 103(9):e427-e431, 2018. PMID: 29773603
Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li T, Schrank-Hacker, A, Morrissette, JJD, Carroll M, June CH, Grupp SA, Gill S. Optimized Depletion of Chimeric Antigen Receptor T-cell Immunotherapy in Murine Xenograft Models of Human Acute Myeloid Leukemia. Blood. 2017 Apr; 129(17): 2395-2407, 2017. PMID: 28246194
Tasian SK, Hurtz C, Wertheim GB, Bailey, NG, Lim MM, Harvey RC, Chen I-M, Willman CL, Astles R, Zebrowski A, Reshmi SC, Li MM, Frey NV, Luger SM, Carroll M, Perl AE. High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL. Leukemia. 2017 Apr; 31(4): 981-984, 2017. PMID: 27932787
Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen I-M, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA. Potent Efficacy of Combined PI3K/mTOR and JAK or ABL Inhibition in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia. Blood. 2017 Jan; 129(2): 177-187, 2017. PMID: 27777238